Anders, C. K. and L. A. Carey (2009). "Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer." Clin Breast Cancer 9 Suppl 2: S73-81.
Bae, S. Y., S. J. Nam, Y. Jung, S. B. Lee, B. W. Park, W. Lim, S. H. Jung, H. W. Yang and S. P. Jung (2018). "Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer." Breast Cancer Res Treat 172(2): 437-444.
Cancer Genome Atlas, N. (2012). "Comprehensive molecular portraits of human breast tumours." Nature 490(7418): 61-70.
Chen, H., D. P. Shen, Z. Z. Zhang, J. H. Liu, Y. Y. Shen and X. Z. Ni (2015). "Fibroblast growth factor receptor 4 protein expression and clinicopathological features in gastric cancer." World J Gastroenterol 21(6): 1838-1844.
Cinkaya, A., M. Akin and A. Sengul (2016). "Evaluation of treatment outcomes of triple-negative breast cancer." J Cancer Res Ther 12(1): 150-154.
Coates, A. S., E. P. Winer, A. Goldhirsch, R. D. Gelber, M. Gnant, M. Piccart-Gebhart, B. Thurlimann, H. J. Senn and M. Panel (2015). "Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015." Ann Oncol 26(8): 1533-1546.
DeSantis, C. E., J. Ma, A. Goding Sauer, L. A. Newman and A. Jemal (2017). "Breast cancer statistics, 2017, racial disparity in mortality by state." CA Cancer J Clin 67(6): 439-448.
Dumay, A., J. P. Feugeas, E. Wittmer, J. Lehmann-Che, P. Bertheau, M. Espie, L. F. Plassa, P. Cottu, M. Marty, F. Andre, C. Sotiriou, L. Pusztai and H. de The (2013). "Distinct tumor protein p53 mutants in breast cancer subgroups." Int J Cancer 132(5): 1227-1231.
Foulkes, W. D., I. E. Smith and J. S. Reis-Filho (2010). "Triple-negative breast cancer." N Engl J Med 363(20): 1938-1948.
Giannakakou, P., G. Poy, Z. Zhan, T. Knutsen, M. V. Blagosklonny and T. Fojo (2000). "Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer." Oncogene 19(27): 3078-3085.
Hammond, M. E., D. F. Hayes, M. Dowsett, D. C. Allred, K. L. Hagerty, S. Badve, P. L. Fitzgibbons, G. Francis, N. S. Goldstein, M. Hayes, D. G. Hicks, S. Lester, R. Love, P. B. Mangu, L. McShane, K. Miller, C. K. Osborne, S. Paik, J. Perlmutter, A. Rhodes, H. Sasano, J. N. Schwartz, F. C. Sweep, S. Taube, E. E. Torlakovic, P. Valenstein, G. Viale, D. Visscher, T. Wheeler, R. B. Williams, J. L. Wittliff and A. C. Wolff (2010). "American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer." J Clin Oncol 28(16): 2784-2795.
Hsu, C. Y., D. M. Ho, C. F. Yang, C. R. Lai, I. T. Yu and H. Chiang (2002). "Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest." Am J Clin Pathol 118(5): 693-698.
Huang, H. P., H. Feng, H. B. Qiao, Z. X. Ren and G. D. Zhu (2015). "The prognostic significance of fibroblast growth factor receptor 4 in non-small-cell lung cancer." Onco Targets Ther 8: 1157-1164.
Inokuchi, M., H. Murase, S. Otsuki, T. Kawano and K. Kojima (2017). "Different clinical significance of FGFR1-4 expression between diffuse-type and intestinal-type gastric cancer." World J Surg Oncol 15(1): 2.
Jiang, Y., S. Sun, W. Wei, Y. Ren, J. Liu and D. Pang (2015). "Association of FGFR3 and FGFR4 gene polymorphisms with breast cancer in Chinese women of Heilongjiang province." Oncotarget 6(32): 34023-34029.
Joshi, J. J., H. Coffey, E. Corcoran, J. Tsai, C. L. Huang, K. Ichikawa, S. Prajapati, M. H. Hao, S. Bailey, J. Wu, V. Rimkunas, C. Karr, V. Subramanian, P. Kumar, C. MacKenzie, R. Hurley, T. Satoh, K. Yu, E. Park, N. Rioux, A. Kim, W. G. Lai, L. Yu, P. Zhu, S. Buonamici, N. Larsen, P. Fekkes, J. Wang, M. Warmuth, D. J. Reynolds, P. G. Smith and A. Selvaraj (2017). "H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma." Cancer Res 77(24): 6999-7013.
Katoh, M. and H. Nakagama (2014). "FGF receptors: cancer biology and therapeutics." Med Res Rev 34(2): 280-300.
Li, C. S., S. X. Zhang, H. J. Liu, Y. L. Shi, L. P. Li, X. B. Guo and Z. H. Zhang (2014). "Fibroblast growth factor receptor 4 as a potential prognostic and therapeutic marker in colorectal cancer." Biomarkers 19(1): 81-85.
Li, Y. W., J. Xu, G. Y. Zhu, Z. J. Huang, Y. Lu, X. Q. Li, N. Wang and F. X. Zhang (2018). "Apigenin suppresses the stem cell-like properties of triple-negative breast cancer cells by inhibiting YAP/TAZ activity." Cell Death Discov 4: 105.
Metzger-Filho, O., A. Tutt, E. de Azambuja, K. S. Saini, G. Viale, S. Loi, I. Bradbury, J. M. Bliss, H. A. Azim, Jr., P. Ellis, A. Di Leo, J. Baselga, C. Sotiriou and M. Piccart-Gebhart (2012). "Dissecting the heterogeneity of triple-negative breast cancer." J Clin Oncol 30(15): 1879-1887.
Motylewska, E., T. Stepien, M. Borkowska, K. Kuzdak, A. Siejka, J. Komorowski, H. Stepien and H. Lawnicka (2018). "Alteration in the serum concentrations of FGF19, FGFR4 and betaKlotho in patients with thyroid cancer." Cytokine 105: 32-36.
Murase, H., M. Inokuchi, Y. Takagi, K. Kato, K. Kojima and K. Sugihara (2014). "Prognostic significance of the co-overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer." Mol Clin Oncol 2(4): 509-517.
Olopade, O. I., T. A. Grushko, R. Nanda and D. Huo (2008). "Advances in breast cancer: pathways to personalized medicine." Clin Cancer Res 14(24): 7988-7999.
Penault-Llorca, F., F. Bertucci, J. Adelaide, P. Parc, F. Coulier, J. Jacquemier, D. Birnbaum and O. deLapeyriere (1995). "Expression of FGF and FGF receptor genes in human breast cancer." Int J Cancer 61(2): 170-176.
Quintanal-Villalonga, A., A. Carranza-Carranza, R. Melendez, I. Ferrer, S. Molina-Pinelo and L. Paz-Ares (2017). "Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement." Clin Lung Cancer 18(6): 667-674 e661.
Quintanal-Villalonga, A., L. Ojeda-Marquez, A. Marrugal, P. Yague, S. Ponce-Aix, A. Salinas, A. Carnero, I. Ferrer, S. Molina-Pinelo and L. Paz-Ares (2018). "The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction." Sci Rep 8(1): 2394.
Shim, H. J., M. H. Shin, H. N. Kim, J. H. Kim, J. E. Hwang, W. K. Bae, I. J. Chung and S. H. Cho (2016). "The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy." Cancer Res Treat 48(1): 71-79.
Sun, S., Y. Jiang, G. Zhang, H. Song, X. Zhang, Y. Zhang, X. Liang, Q. Sun and D. Pang (2012). "Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer." J Surg Oncol 105(8): 773-779.
Sun, S., X. Liang, X. Zhang, T. Liu, Q. Shi, Y. Song, Y. Jiang, H. Wu, Y. Jiang, X. Lu and D. Pang (2015). "Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer." Br J Cancer 112(8): 1332-1339.
Thisse, B. and C. Thisse (2005). "Functions and regulations of fibroblast growth factor signaling during embryonic development." Dev Biol 287(2): 390-402.
Thussbas, C., J. Nahrig, S. Streit, J. Bange, M. Kriner, R. Kates, K. Ulm, M. Kiechle, H. Hoefler, A. Ullrich and N. Harbeck (2006). "FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer." J Clin Oncol 24(23): 3747-3755.
Tiong, K. H., B. S. Tan, H. L. Choo, F. F. Chung, L. W. Hii, S. H. Tan, N. T. Khor, S. F. Wong, S. J. See, Y. F. Tan, R. Rosli, S. K. Cheong and C. O. Leong (2016). "Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival." Oncotarget 7(36): 57633-57650.
Tomlinson, E., L. Fu, L. John, B. Hultgren, X. Huang, M. Renz, J. P. Stephan, S. P. Tsai, L. Powell-Braxton, D. French and T. A. Stewart (2002). "Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity." Endocrinology 143(5): 1741-1747.
Wei, W., Z. You, S. Sun, Y. Wang, X. Zhang, D. Pang and Y. Jiang (2018). "Prognostic implications of fibroblast growth factor receptor 4 polymorphisms in primary breast cancer." Mol Carcinog 57(8): 988-996.
Xu, M., S. Chen, W. Yang, X. Cheng, Y. Ye, J. Mao, X. Wu, L. Huang and J. Ji (2018). "FGFR4 Links Glucose Metabolism and Chemotherapy Resistance in Breast Cancer." Cell Physiol Biochem 47(1): 151-160.
Yu, C., F. Wang, M. Kan, C. Jin, R. B. Jones, M. Weinstein, C. X. Deng and W. L. McKeehan (2000). "Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4." J Biol Chem 275(20): 15482-15489.
Yu, S., L. Zheng, D. K. Trinh, S. L. Asa and S. Ezzat (2004). "Distinct transcriptional control and action of fibroblast growth factor receptor 4 in differentiating skeletal muscle cells." Lab Invest 84(12): 1571-1580.
Zeng, K., B. He, B. B. Yang, T. Xu, X. Chen, M. Xu, X. Liu, H. Sun, Y. Pan and S. Wang (2018). "The pro-metastasis effect of circANKS1B in breast cancer." Mol Cancer 17(1): 160.
Zhao, P., G. Caretti, S. Mitchell, W. L. McKeehan, A. L. Boskey, L. M. Pachman, V. Sartorelli and E. P. Hoffman (2006). "Fgfr4 is required for effective muscle regeneration in vivo. Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway." J Biol Chem 281(1): 429-438.
Zhao, X., F. Xu, N. P. Dominguez, Y. Xiong, Z. Xiong, H. Peng, C. Shay and Y. Teng (2018). "FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression." Mol Carcinog 57(11): 1616-1625.